
Paramedics in Waterloo region say resources are starting to 'match the demand for our service'
It was only a few years ago when paramedics in Waterloo region were sounding the alarm about being overworked and lacking necessary resources to effectively do their jobs, but recently they say there's hope.
At the end of 2022, Waterloo region experienced weekly Code Red events, meaning there were no ambulances available to respond to emergency calls.
This was caused by a variety of factors including being understaffed, long offloading times at hospitals and the overall increase for service demand that was brought on by the COVID-19 pandemic.
John Riches is the chief of Waterloo region's paramedic services. He says things are looking much better.
"In 2022, we were at a bit of a precipice where yes, investments were being made, but the number of Code Zero or Code Red events were still significant," Riches explained.
"What we're seeing now after the year of 2024 and still seeing it now into 2025, is that the number of resources we have are starting to be able to match the demand for our service."
Though Code Reds, now known as Code Zeros, are still happening once in a while, it's nowhere near the severity that it was during the peak of the pandemic.
In 2022, Waterloo region had 210 Code Red events, totalling roughly 76 hours, according to the region's performance measurement indicators update from that year.
A stark difference compared to 2024's year-to-date update released in September, indicating approximately 14 hours were spent in code red.
Riches attributes much of the improving metrics to the Region of Waterloo's council supporting an expansion for paramedic services.
Back in September 2023, it was announced that local paramedic services would receive $4.4 million to hire more staff.
The region also received an additional $1.65 million from the province for a designated offload nurse program.
"During peak deployment, we now have 40 staff resources available on the road and overnight that drops to 20, obviously because call demand drops overnight while people are sleeping."
As a result, emergency response times have also improved.
On average, regional paramedics were responding to calls in 2024 within nine minutes and six seconds. That's 22 seconds faster than 2023, when they were responding within nine minutes and 28 seconds.
"We do sometimes see response times lengthened out in the rural townships because there's a wide geography out there and it takes longer to get the calls," Riches explained.
Hospital offload delays
Although there are still available ambulances, hospital offload delays continue to remain long, though Riches says they're significantly decreasing.
Offload time refers to the period that begins when paramedics arrive at the emergency department and ends when their patient is placed in a bed and care is handed over to ER staff.
As of June 2024, paramedic services had lost an average of 47 hours over a 12 month period due to offload delays. This is equivalent to nearly four, 12-hour ambulance shifts per day.
"I think the biggest change that I've seen in the two years that I've been with the region is that our hospital partners are fully invested and involved at a senior executive level to improve ambulance offload time within the emergency departments," said Riches.
"It's no longer just an emergency department issue to deal with, they're asking the whole hospital to support the work. So that kind of buy-in to addressing the problem has probably been the single biggest thing that has improved ambulance offload times."
Burn out and exhaustion
As working conditions continue to improve for paramedics due to resources becoming more accessible, workers are feeling the benefits as well.
During the pandemic, there were many reports across the country of paramedics feeling burned out and exhausted from the demands of their work.
Now, Riches says there are indications his medics are slowly but surely recovering.
"They work in really challenging circumstances, in unusual situations in which the environment can be unsafe and they do an amazing job everyday," he said.
"I certainly am hearing from paramedics that they're not missing meal breaks … We're also seeing reduced end of shift overtimes, which is also an indicator that we have resource availability so we can get our paramedics off on time."
While those factors show a trend in the right direction, Nick Desclouds says they're not out of the water just yet.
"Mental health is still something that we really have to strongly advocate for," said the President of CUPE Local 5191, the union representing Waterloo region's paramedics.
Desclouds is also a paramedic himself.
"The career is difficult so having ways that we can support each other in the workplace and not having that overwhelming volume every single day we show up to work, it's definitely going to help improve that," he added.
The Region of Waterloo's Paramedic Services has a 10-year master plan that outlines investments within that time period. The current plan expires at the end of 2027.
"Things have changed so much coming out of the pandemic and population growth, which results in an increase of 911 calls," Riches explained.
"We are engaging in a new master plan development and once that master plan gets adopted and approved by council, that would take over for the current master plan and would start in 2026 to 2035."
Within that time frame, the Region of Waterloo plans to open a new hospital located on the University of Waterloo campus. Something Riches says would be a big change in terms of the service paramedics will be able to deliver to residents.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Japan Forward
7 hours ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む


Global News
2 days ago
- Global News
RFK Jr. removes all 17 members of U.S. vaccine advisory panel
U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the Biden administration had installed the entire committee. 'Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028,' Kennedy wrote in a Wall Street Journal opinion piece. 'A clean sweep is needed to re-establish public confidence in vaccine science.' Story continues below advertisement Kennedy said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster 'a coup.' 'It's not how democracies work. It's not good for the health of the nation,' Benjamin told The Associated Press. 0:37 RFK announces COVID vaccine removal from immunization schedule for pregnant women and children Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy 'like a hawk.' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'He is breaking a promise,' Benjamin said. 'He said he wasn't going to do this.' Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases. Story continues below advertisement 'Today's action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives,' Scott said in a statement. Republican Sen. Bill Cassidy of Louisiana, a doctor who had expressed reservations about Kennedy's nomination but voted to install him as the nation's health secretary nonetheless, said he had spoken with Kennedy moments after the announcement. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy said in a social media post. 'I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' 9:34 RFK Jr. and Elizabeth Warren get into heated debate over vaccine question at confirmation hearing The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Story continues below advertisement During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations. Kennedy did not stick to that. He recently took the unusual step of changing COVID-19 recommendations without first consulting the advisers. The webpage that featured the committee's members was deleted Monday evening, shortly after Kennedy's announcement.


Winnipeg Free Press
2 days ago
- Winnipeg Free Press
RFK Jr. ousts entire CDC vaccine advisory committee
WASHINGTON (AP) — Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. The 17-member Advisory Committee on Immunization Practices had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, recently took the unusual step of changing COVID-19 recommendations without first consulting the panel. Kennedy, in a Wall Street Journal opinion piece, said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.